To evaluate the effectiveness of the Shamir Myopia Control lens in slowing myopia progression in children aged 6-13 over 24 months.
Key Findings:
The Shamir Myopia Control lens group showed a 26% reduction in spherical equivalent refraction (SER) progression compared to the control group (0.76 D vs 1.03 D, p < 0.05), indicating a clinically meaningful impact.
Axial length elongation was reduced by 34% in the Shamir lens group compared to the control group (0.33 mm vs 0.50 mm, p < 0.01).
Both groups reported high satisfaction with their visual experience and compliance with lens wear.
Interpretation:
The Shamir Myopia Control lens effectively slows myopia progression in children, demonstrating significant reductions in both SER and axial length elongation over 24 months.
Limitations:
High dropout rate (38%) due to various reasons, including external factors like the October 7 attack, which may have influenced participant retention.
Potential bias in self-reported comfort and satisfaction measures.
Conclusion:
The study supports the use of the Shamir Myopia Control lens as a viable option for managing myopia progression in children, with significant clinical benefits observed over two years, suggesting avenues for future research.
